Chimeric antigen receptor-engineered T cells in CLL: the next chapter unfolds

The long-standing promise for the application of engineered T lymphocytes to target and eradicate malignancy has begun to be realized recently, with remarkable clinical success reported by a number of groups using Chimeric Antigen Receptor –engineered T cells to target CD19-positive hematologic mali...

Descripción completa

Detalles Bibliográficos
Autor principal: Kalos, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754893/
https://www.ncbi.nlm.nih.gov/pubmed/26885367
http://dx.doi.org/10.1186/s40425-016-0108-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754893/
https://www.ncbi.nlm.nih.gov/pubmed/26885367
http://dx.doi.org/10.1186/s40425-016-0108-2

Ejemplares similares